Navigation Links
GenoSpace Expands Its Management Team by Appointing Daniel Meyer as Chief Financial Officer

CAMBRIDGE, Mass., March 28, 2013 /PRNewswire/ -- GenoSpace, LLC, a company that builds information systems capable of storing and integrating genomic information and other health data for clinical care and advanced research, today announced the addition of Daniel Meyer as Chief Financial Officer.


"We have been working with Dan in an advisory relationship since forming the company, and are pleased to be able to bring him on full time," stated John Quackenbush , PhD., CEO of GenoSpace. "The GenoSpace team has produced incredible successes since we launched and we are getting excellent feedback from our customers and users at clinical labs and research institutions. Our ability to build the senior management team reflects the rapidly growing scale of our business and quality of our pipeline."

Mr. Meyer has spent his entire career in life sciences entrepreneurship, venture capital and investment banking. He covered the healthcare portfolios at Arboretum Ventures and Point Judith Capital, where he focused on investments in life science tools, medical devices, healthcare information technology and services. Prior to his work investing in early stage companies, Mr. Meyer was a member of the health care investment banking team at Credit Suisse First Boston. He was also a co-founder and the General Manager of a medical device startup from inception through prototype development. Mr. Meyer holds a B.A. in Mathematics and Economics from Middlebury College and an M.B.A. from the Tuck School of Business at Dartmouth.

About GenoSpace
At GenoSpace, we are Digital Architects of Genomic Medicine™. GenoSpace is a Cambridge, Massachusetts-based company that has developed robust software systems for securely storing vast amounts of genomic and health data, and providing it in formats specific to its diverse user communities. GenoSpace for Clinical Care™ facilitates clinically actionable interpretation and report generation for precision medicine. GenoSpace for Research™ provides dynamic analysis, visualization and collaboration tools. GenoSpace for Patient Communities™ enables patient-centric exploration and advancement of personalized medicine.

GenoSpace has created an information ecosystem for 21st century genomic medicine—one that enables different participants in precision medicine to realize the potential of our ever-expanding knowledge of human disease and its treatment. Please visit for more information.

Company Contact:
John Quackenbush
Chief Executive Officer
GenoSpace, LLC

Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
2. GLM Displays Expands Its Line of Formulate Fabric Displays with the Vibe 10ft Display
3. Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
4. Leading Chemical Manufacturer Expands Biobased Offering through Unique Distribution of Proven Green Spill Absorbent
5. Defying Industry Trends, BBK Worldwide Expands Ownership From Within
6. Abacus International Expands Annual Partnership With HealthEconomics.Com
7. Personal Genome Diagnostics Inc. Licenses Genome-Mapping Technology from Johns Hopkins University and Expands Its Cancer Genome Analysis Business
8. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey
9. SAFC Expands Irvine Facility to Add Dry Powder Media Manufacturing Capabilities
10. Genomas Expands Personalized Medicine Business with Clinical Laboratory Licenses in New York, Florida, California
11. XBiotech Expands Portfolio to Include Biosimilars
Post Your Comments:
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... Studies reveal the differences in ... pave the way for more effective treatment for one of ...   --> --> Gum ... in cats, yet relatively little was understood about the bacteria ... been conducted by researchers from the WALTHAM Centre for Pet ...
(Date:11/25/2015)... QUEBEC CITY , Nov. 25, 2015 /PRNewswire/ ... "Company"), affirms that its business and prospects remain ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB ... program to completion following review of the final ... met Phase 2 Primary Endpoint in men with ...
(Date:11/25/2015)... , November 25, 2015 ... Report is a professional and in-depth study on ...      (Logo: ) , ... the industry including definitions, classifications, applications and industry ... for the international markets including development trends, competitive ...
Breaking Biology Technology:
(Date:11/19/2015)... 2015  Although some 350 companies are actively involved ... few companies, according to Kalorama Information. These include Roche Diagnostics, ... market share of the 6.1 billion-dollar molecular testing market, ... for Molecular Diagnostic s .    ... controlled by one company and only a handful of ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces ... joined its Board of Directors. --> ... after recently retiring from the partnership at TPG Capital, ... companies with over $140 Billion in revenue.  He founded ... across all the TPG companies, from 1997 to 2013.  ...
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
Breaking Biology News(10 mins):